Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 2
2005 3
2006 3
2007 14
2008 6
2009 4
2010 1
2011 16
2012 8
2013 9
2014 15
2015 8
2016 9
2017 10
2018 12
2019 7
2020 28
2021 19
2022 14
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Results by year

Filters applied: . Clear all
Page 1
Incidence of acute kidney injury (AKI) and its impact on patient outcomes among adult hospitalized patients with carbapenem-resistant Gram-negative infections who received targeted treatment with a newer β-lactam or β-lactam/β-lactamase inhibitor-, polymyxin- or aminoglycoside-containing regimen.
Lodise TP, Yucel E, Obi EN, Watanabe AH, Nathanson BH. Lodise TP, et al. J Antimicrob Chemother. 2024 Jan 3;79(1):82-95. doi: 10.1093/jac/dkad351. J Antimicrob Chemother. 2024. PMID: 37962080 Free PMC article.
Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group.
Satlin MJ, van Duin D, Tamma PD, Lodise TP, Van Tyne D, Rodvold KA, Rouphael N, Evans SR, Fowler VG, Hamasaki T, Patel R, Komarow L, Baum K, Souli M, Schwager N, Bonomo RA, Doi Y; Antibacterial Resistance Leadership Group. Satlin MJ, et al. Among authors: lodise tp. Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S305-S313. doi: 10.1093/cid/ciad547. Clin Infect Dis. 2023. PMID: 37843118
Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review.
Doernberg SB, Arias CA, Altman DR, Babiker A, Boucher HW, Creech CB, Cosgrove SE, Evans SR, Fowler VG, Fritz SA, Hamasaki T, Kelly BJ, Leal SM, Liu C, Lodise TP, Miller LG, Munita JM, Murray BE, Pettigrew MM, Ruffin F, Scheetz MH, Shopsin B, Tran TT, Turner NA, Williams DJ, Zaharoff S, Holland TL; Antibacterial Resistance Leadership Group. Doernberg SB, et al. Among authors: lodise tp. Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S295-S304. doi: 10.1093/cid/ciad565. Clin Infect Dis. 2023. PMID: 37843115 Review.
Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection.
Straub TJ, Lombardo MJ, Bryant JA, Diao L, Lodise TP, Freedberg DE, Wortman JR, Litcofsky KD, Hasson BR, McGovern BH, Ford CB, Henn MR. Straub TJ, et al. Among authors: lodise tp. Clin Infect Dis. 2024 Apr 10;78(4):833-841. doi: 10.1093/cid/ciad636. Clin Infect Dis. 2024. PMID: 37823484 Free PMC article. Clinical Trial.
Clinical Risk Scores to Predict Nonsusceptibility to Trimethoprim-Sulfamethoxazole, Fluoroquinolone, Nitrofurantoin, and Third-Generation Cephalosporin Among Adult Outpatient Episodes of Complicated Urinary Tract Infection.
Lodise TP, Chen LH, Wei R, Im TM, Contreras R, Bruxvoort KJ, Rodriguez M, Friedrich L, Tartof SY. Lodise TP, et al. Open Forum Infect Dis. 2023 Jun 14;10(8):ofad319. doi: 10.1093/ofid/ofad319. eCollection 2023 Aug. Open Forum Infect Dis. 2023. PMID: 37534299 Free PMC article.
Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections.
Lodise TP, Gunter K, Mu F, Gao E, Yang D, Yim E, Sandor S, Berman G. Lodise TP, et al. J Manag Care Spec Pharm. 2023 Aug;29(8):952-964. doi: 10.18553/jmcp.2023.22454. Epub 2023 Jun 12. J Manag Care Spec Pharm. 2023. PMID: 37307087 Free PMC article.
Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial.
Tamma PD, Souli M, Billard M, Campbell J, Conrad D, Ellison DW, Evans B, Evans SR, Greenwood-Quaintance KE, Filippov AA, Geres HS, Hamasaki T, Komarow L, Nikolich MP, Lodise TP, Nayak SU, Norice-Tra C, Patel R, Pride D, Russell J, Van Tyne D, Chambers HF, FowlerJr VG, Schooley RT; Antibacterial Resistance Leadership Group. Tamma PD, et al. Among authors: lodise tp. Trials. 2022 Dec 28;23(1):1057. doi: 10.1186/s13063-022-07047-5. Trials. 2022. PMID: 36578069 Free PMC article.
179 results